Plasma based markers of [11C] PiB-PET brain amyloid burden.
Changes in brain amyloid burden have been shown to relate to Alzheimer's disease pathology, and are believed to precede the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are able to accurately estimate brain amyloid burden as a ma...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0044260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849470611528613888 |
|---|---|
| author | Steven John Kiddle Madhav Thambisetty Andrew Simmons Joanna Riddoch-Contreras Abdul Hye Eric Westman Ian Pike Malcolm Ward Caroline Johnston Michelle Katharine Lupton Katie Lunnon Hilkka Soininen Iwona Kloszewska Magda Tsolaki Bruno Vellas Patrizia Mecocci Simon Lovestone Stephen Newhouse Richard Dobson Alzheimers Disease Neuroimaging Initiative |
| author_facet | Steven John Kiddle Madhav Thambisetty Andrew Simmons Joanna Riddoch-Contreras Abdul Hye Eric Westman Ian Pike Malcolm Ward Caroline Johnston Michelle Katharine Lupton Katie Lunnon Hilkka Soininen Iwona Kloszewska Magda Tsolaki Bruno Vellas Patrizia Mecocci Simon Lovestone Stephen Newhouse Richard Dobson Alzheimers Disease Neuroimaging Initiative |
| author_sort | Steven John Kiddle |
| collection | DOAJ |
| description | Changes in brain amyloid burden have been shown to relate to Alzheimer's disease pathology, and are believed to precede the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are able to accurately estimate brain amyloid burden as a marker of Alzheimer's disease. One potential method would involve using demographic information and measurements on plasma samples to establish biomarkers of brain amyloid burden; in this study data from the Alzheimer's Disease Neuroimaging Initiative was used to explore this possibility. Sixteen of the analytes on the Rules Based Medicine Human Discovery Multi-Analyte Profile 1.0 panel were found to associate with [(11)C]-PiB PET measurements. Some of these markers of brain amyloid burden were also found to associate with other AD related phenotypes. Thirteen of these markers of brain amyloid burden--c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and immunoglobulin E--were used along with co-variates in multiple linear regression, and were shown by cross-validation to explain >30% of the variance of brain amyloid burden. When a threshold was used to classify subjects as PiB positive, the regression model was found to predict actual PiB positive individuals with a sensitivity of 0.918 and a specificity of 0.545. The number of APOE [Symbol: see text] 4 alleles and plasma apolipoprotein E level were found to contribute most to this model, and the relationship between these variables and brain amyloid burden was explored. |
| format | Article |
| id | doaj-art-0068a6795ecf429f942edab1cbd38f4b |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-0068a6795ecf429f942edab1cbd38f4b2025-08-20T03:25:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4426010.1371/journal.pone.0044260Plasma based markers of [11C] PiB-PET brain amyloid burden.Steven John KiddleMadhav ThambisettyAndrew SimmonsJoanna Riddoch-ContrerasAbdul HyeEric WestmanIan PikeMalcolm WardCaroline JohnstonMichelle Katharine LuptonKatie LunnonHilkka SoininenIwona KloszewskaMagda TsolakiBruno VellasPatrizia MecocciSimon LovestoneStephen NewhouseRichard DobsonAlzheimers Disease Neuroimaging InitiativeChanges in brain amyloid burden have been shown to relate to Alzheimer's disease pathology, and are believed to precede the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are able to accurately estimate brain amyloid burden as a marker of Alzheimer's disease. One potential method would involve using demographic information and measurements on plasma samples to establish biomarkers of brain amyloid burden; in this study data from the Alzheimer's Disease Neuroimaging Initiative was used to explore this possibility. Sixteen of the analytes on the Rules Based Medicine Human Discovery Multi-Analyte Profile 1.0 panel were found to associate with [(11)C]-PiB PET measurements. Some of these markers of brain amyloid burden were also found to associate with other AD related phenotypes. Thirteen of these markers of brain amyloid burden--c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and immunoglobulin E--were used along with co-variates in multiple linear regression, and were shown by cross-validation to explain >30% of the variance of brain amyloid burden. When a threshold was used to classify subjects as PiB positive, the regression model was found to predict actual PiB positive individuals with a sensitivity of 0.918 and a specificity of 0.545. The number of APOE [Symbol: see text] 4 alleles and plasma apolipoprotein E level were found to contribute most to this model, and the relationship between these variables and brain amyloid burden was explored.https://doi.org/10.1371/journal.pone.0044260 |
| spellingShingle | Steven John Kiddle Madhav Thambisetty Andrew Simmons Joanna Riddoch-Contreras Abdul Hye Eric Westman Ian Pike Malcolm Ward Caroline Johnston Michelle Katharine Lupton Katie Lunnon Hilkka Soininen Iwona Kloszewska Magda Tsolaki Bruno Vellas Patrizia Mecocci Simon Lovestone Stephen Newhouse Richard Dobson Alzheimers Disease Neuroimaging Initiative Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS ONE |
| title | Plasma based markers of [11C] PiB-PET brain amyloid burden. |
| title_full | Plasma based markers of [11C] PiB-PET brain amyloid burden. |
| title_fullStr | Plasma based markers of [11C] PiB-PET brain amyloid burden. |
| title_full_unstemmed | Plasma based markers of [11C] PiB-PET brain amyloid burden. |
| title_short | Plasma based markers of [11C] PiB-PET brain amyloid burden. |
| title_sort | plasma based markers of 11c pib pet brain amyloid burden |
| url | https://doi.org/10.1371/journal.pone.0044260 |
| work_keys_str_mv | AT stevenjohnkiddle plasmabasedmarkersof11cpibpetbrainamyloidburden AT madhavthambisetty plasmabasedmarkersof11cpibpetbrainamyloidburden AT andrewsimmons plasmabasedmarkersof11cpibpetbrainamyloidburden AT joannariddochcontreras plasmabasedmarkersof11cpibpetbrainamyloidburden AT abdulhye plasmabasedmarkersof11cpibpetbrainamyloidburden AT ericwestman plasmabasedmarkersof11cpibpetbrainamyloidburden AT ianpike plasmabasedmarkersof11cpibpetbrainamyloidburden AT malcolmward plasmabasedmarkersof11cpibpetbrainamyloidburden AT carolinejohnston plasmabasedmarkersof11cpibpetbrainamyloidburden AT michellekatharinelupton plasmabasedmarkersof11cpibpetbrainamyloidburden AT katielunnon plasmabasedmarkersof11cpibpetbrainamyloidburden AT hilkkasoininen plasmabasedmarkersof11cpibpetbrainamyloidburden AT iwonakloszewska plasmabasedmarkersof11cpibpetbrainamyloidburden AT magdatsolaki plasmabasedmarkersof11cpibpetbrainamyloidburden AT brunovellas plasmabasedmarkersof11cpibpetbrainamyloidburden AT patriziamecocci plasmabasedmarkersof11cpibpetbrainamyloidburden AT simonlovestone plasmabasedmarkersof11cpibpetbrainamyloidburden AT stephennewhouse plasmabasedmarkersof11cpibpetbrainamyloidburden AT richarddobson plasmabasedmarkersof11cpibpetbrainamyloidburden AT alzheimersdiseaseneuroimaginginitiative plasmabasedmarkersof11cpibpetbrainamyloidburden |